COVID vaccination during pregnancy protects infants from hospitalization during their first 6 months of life. Published in ...

The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.

A 4th dose of the bivalent or monovalent Omicron BA.1-adapted BNT162b2 vaccine elicits robust neutralizing responses in adults aged 18 to 55.

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

CDC panel advises tracking COVID-19 vaccine injuries by establishing new ICD-10 codes and clinical guidelines to improve diagnosis and care.

We received hundreds of queries about efficacy, safety, cost and access. By The New York Times The vaccine situation in the United States has become chaotic, and it can be hard to keep up. An advisory ...

A registry study across 14 Japanese clinics analyzed 179 cases of post-COVID-19 vaccination syndrome (PCVS) and identified ...

The US Centers for Disease Control and Prevention signed off on a recommendation that patients must consult a health care provider to get a Covid-19 vaccine, although they don’t necessarily need a ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...